Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 0855 • ACR Convergence 2025
Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
Jane Salmon¹, Mimi Kim², Marta Guerra¹, Joseph Worden³, Carl Laskin⁴, Maria DeSancho⁵, Inna Landres⁵, Jason S. Knight⁶, Haley Slosberg¹, Margaret Minett¹ and Ware Branch⁷, ¹Hospital for Special Surgery, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³University of Utah School of Medicine, Salt Lake City, ⁴University of Toronto, Toronto, ON, Canada, ⁵Weill Cornell Medicine, New York, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Utah Health Sciences Center, Salt Lake City, UT
Background/Purpose: The IMPACT trial (NCT03152058) showed that certolizumab appears effective in preventing placenta-mediated adverse pregnancy outcome (APO) in high-risk antiphospholipid syndrome (APS) patients. We have…
Abstract Number: 2267 • ACR Convergence 2025
Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
Chris Edwards¹, Janet Pope², Joelle Monnet³ and Maria Romanova Michailidi⁴, ¹University Hospital Southampton, Southampton, United Kingdom, ²University of Western Ontario, London, ON, Canada, ³Fresenius Kabi SwissBioSim, Eysins, Switzerland, ⁴University of Geneva, Eysins, Switzerland
Background/Purpose: RA has been associated with an increase risk of cardiovascular morbidity and mortality1. The present analysis was performed to assess the efficacy (on ACR…
Abstract Number: 0537 • ACR Convergence 2025
HLA-B27 and Axial Involvement as Independent Risk Factors for Uveitis in Spondyloarthritis: New Insights from a 15-Year Real-Life Study
Kent LE¹, Hervé LOCRELLE¹, Myriam NORMAND¹, Irina COMAN¹, Louis DELENTE¹, Tiphany NEEL¹, Adamah AMOUZOUGAN¹, Thierry THOMAS¹ and Hubert Marotte², ¹Service Rhumatologie Hôpital Nord, Saint-Etienne, France, ²INSERM ¹⁰⁵⁹/University of Saint-Etienne, Saint-Etienne, France
Background/Purpose: To assess the prevalence, risk factors and treatment-related outcomes of uveitis in patients with spondyloarthritis (SpA), using data from a 15-year real-life cohort.Methods: We…
Abstract Number: 2042 • ACR Convergence 2025
Safety and Effectiveness of the Use of Combined Therapy with bDMARDS and tsDMARDs in Immune-mediated Inflammatory Diseases
Natalia Lopez Juanes¹, Carlota Ureta¹, Marta Novella-Navarro¹, Irene Monjo Henry¹, Diana Peiteado¹, Alejandro Villalba¹, Laura Nuño², Victoria Navarro-Compan³, María Sanz¹, Mª ángeles Gonzalez¹, Cristina Suarez⁴, Agustin Remesal¹, Rosa Alcobendas⁵, Clara udaondo¹, Elena Sendagorta⁵, Alejandro Balsa¹, Eugenio de Miguel¹ and Chamaida Plasencia-Rodríguez¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁵La Paz University Hospital, Madrid, Spain
Background/Purpose: The combination of biological (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has emerged as a promising approach to improve clinical outcomes in immune-mediated inflammatory diseases…
Abstract Number: 0504 • ACR Convergence 2025
Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis
Vincent Wong¹, Katie Lowe², Annabelle Small³, Christopher Altmann³, Susanna Proudman⁴, Malcolm Smith², Wittaya Suwakulsiri⁵, Ranjeny Thomas⁵, Chung Hoow Kok⁶ and Mihir Wechalekar⁷, ¹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ²Flinders University, Adelaide, South Australia, Australia, ³Flinders University, Bedford Park, South Australia, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ⁶Centre for Cancer Biology, and Clinical Health Sciences, University of South Australia, Adelaide, South Australia, Australia, ⁷Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Rheumatoid arthritis (RA) shows heterogeneous therapeutic responses that may reflect diversity within synovial tissue (ST). We aimed to identify gene signatures that predict Adalimumab…
Abstract Number: 1677 • ACR Convergence 2025
First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
Task Toyoda¹, Kerem Abacar¹, Farag Shuweihdi², Megan Sheridan³, Jacqueline Nam³, Ai Lyn Tan⁴, Lesley-Anne Bissell³, Paul Emery⁵ and Kulveer Mankia⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ²Dental Translational and Clinical Research Unit, School of Medicine, University of Leeds, Leeds, England, United Kingdom, ³Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ⁵University of Leeds, Leeds, England, United Kingdom
Background/Purpose: While conventional synthetic DMARDs (csDMARDs) remain first line therapy in early RA, most patients do not achieve sustained remission, and a subgroup develop difficult-to-treat…
Abstract Number: 0496 • ACR Convergence 2025
Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
Mitndbaim Parra¹, Rafaela Ortega-Castro², Jerusalén Calvo³, Francisco Jose Cepas⁴, Montserrat Robustillo-Villarino⁵, Andres Zuniga-Vera⁵, Ana Martinez-Feito⁶, Chamaida Plasencia-Rodríguez⁷, Ester Costa-Moya⁸, Delia Taverner-Torrent⁸, Luis Sainz Comas⁹, Cesar Diaz-Torne⁹, Virginia Ruiz-Esquide¹⁰, Cynthia Rojas¹¹, Lourdes Martin-de la Sierra Lopez¹², Laura Jimenez-Rodriguez¹², David Velasco-Sanchez¹², Regina Fará Garcia¹³, Antonio Juan-Mas¹⁴, Marina soledad Moreno Garcia¹⁵, Ana Valeria Acosta Alfaro¹⁶, Santiago Muñoz¹⁷, Maria Martín López¹⁸, Raquel Zas¹⁹, FRANCISCO JAVIER GODOY NAVARRETE²⁰, Isabel Anon Onate²¹, Fernando Ortiz-Márquez²², Natalia Mena Vázquez²³, Paula Estrada-Alarcón²⁴, Lourdes Ladehesa²⁵, Alejandro Escudero Contreras³ and Clementina López Medina²⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴University of Cordoba, Cordoba, Spain, ⁵Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁶Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁷Hospital Universitario La Paz, MADRID, Spain, ⁸Hospital Sant Joan Reus, Reus, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹¹Hospital Clinic, Barcelona, Spain, ¹²Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹³Hospital Son Llàtzer, Palma, Spain, ¹⁴Son Llazter University Hospital, Madrid, Spain, ¹⁵Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁶Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁷Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁸Hospital ¹² de Octubre, Madrid, Spain, ¹⁹Hospital Universitario Doce de Octubre, Madrid, Spain, ²⁰Jaen University Hospital, Spain, Jaen, Spain, ²¹Hospital Universitario de Jaén, Jaén, Spain, ²²Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²³Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²⁴Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody directed against the Fc fragment of IgG that plays a key role in the development of rheumatoid arthritis…
Abstract Number: 2644 • ACR Convergence 2025
Single Cell RNA-seq Profiling Reveals a Blood Monocyte Phenotype Associated with Response to TNF Inhibitor Therapy in RA Patients
Kathryne Marks¹, Alice Horisberger², Ifeoluwakiisi Adejoorin¹, Leah Santacroce¹, Mehreen Elahee³, Joan Bathon⁴, Kevin Wei⁵, Daniel Solomon⁶ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Lausanne University Hospital (CHUV), Lausanne, Switzerland, ³Brigham and Women's Hospital, Wexford, PA, ⁴Columbia University, NEW YORK, NY, ⁵Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA
Background/Purpose: TNF inhibitors (TNFi) are the most common biologic DMARD used to treat RA; however, no robust biomarkers have been established to predict likelihood of…
Abstract Number: 1664 • ACR Convergence 2025
Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression
Alexia Zagouras¹, Sammy Pickell¹, Yuhan Liu¹, Ronald Witteles¹ and Matthew Charles Baker², ¹Stanford University, Stanford, CA, ²Stanford University, Menlo Park, CA
Background/Purpose: There are no FDA-approved therapies for cardiac sarcoidosis (CS), a disease associated with high morbidity and mortality. Treatment typically consists of glucocorticoids and off-label…
Abstract Number: 0402 • ACR Convergence 2025
Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
Dawn Gist¹, Andrea Ramirez¹, Jamie Lai², Duc Nguyen¹ and Kexin Guo¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, The Woodlands, TX
Background/Purpose: Adalimumab is a monoclonal antibody against TNF-α that is commonly used to treat JIA, hidradenitis suppurativa (HS), chronic uveitis, sarcoidosis, and chronic nonbacterial osteomyelitis…
Abstract Number: 2634 • ACR Convergence 2025
Sex differences in medication discontinuation in axial spondyloarthritis
Rachael Stovall¹, Cinthia Blat², Eric Roberts³, Jean Liew⁴, Katherine Wysham⁵, Namrata Singh¹, Janna Friedly¹, Lianne S. Gensler⁶, gabriela Schmajuk⁷ and Jinoos Yazdany⁸, ¹University of Washington, Seattle, WA, ²University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, SF, CA, ⁴Boston University School of Medicine, Boston, MA, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁸UCSF, San Francisco, CA
Background/Purpose: Women with axial spondyloarthritis (axSpA) tend to report worse outcomes and greater functional impairment than men. They may also respond less favorably to medication,…
Abstract Number: 1657 • ACR Convergence 2025
Extracting TNF Inhibitor Switching Reasons and Trajectories From Real-World Data Using Large Language Models
Brenda Miao¹, Marie Binvignat², Augusto Garcia-Agundez³, Maxim Bravo⁴, Christopher Williams⁵, Claire Miao⁴, Ahmed Alaa⁶, Vivek Rudrapatna⁵, gabriela Schmajuk⁷ and Jinoos Yazdany³, ¹UCSF, Fremont, CA, ²Sorbonne University, Paris, France, ³UCSF, San Francisco, CA, ⁴UC Berkeley, San Francisco, ⁵UCSF, San Francisco, ⁶UC Berkeley, Berkeley, ⁷University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are cornerstones of autoimmune‑disease therapy, yet many patients switch agents because of loss of effectiveness, adverse events, or insurance…
Abstract Number: 0395 • ACR Convergence 2025
Association Between Body Mass Index (BMI) and JIA Inactive Disease at One Year
Anna Sutton¹ and Susan Shenoi², ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital and Research Center, Mercer Island, WA
Background/Purpose: Among adults, higher BMI contributes to worse outcomes and reduced response to treatment in rheumatoid arthritis (RA), but this relationship is understudied among those…
Abstract Number: 2633 • ACR Convergence 2025
Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: To compare safety outcomes in patients with ankylosing spondylitis (AS) initiating Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi).Methods: This retrospective cohort…
Abstract Number: 1446 • ACR Convergence 2025
Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
José Miguel Senabre¹, Lucia Otero², Jerusalén Calvo³, Vega Jovaní⁴, Javier Manero-Ruiz⁵, Rabadán Elena⁶, Eugenia Enriquez⁷, Yanira Pérez⁸, Alicia Garcia⁹, Francisca Sivera¹⁰, Olga Martínez¹¹, María Colazo Burlato¹², Diana Sueiro¹³, Fernando Sánchez-Alonso¹⁴ and Isabel Castrejón Fernández¹⁵, ¹Hospital Marina Baixa, Villajoyosa/Vila Joiosa, La, Comunidad Valenciana, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴Hospital General Universitario de Alicante, Reumatología, Alicante, Alicante, Comunidad Valenciana, Spain, ⁵Hospital Miguel Servet, Zaragoza, Spain, ⁶Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain, ⁷Clínica Universidad de Navarra, Madrid, Spain, ⁸Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ⁹Rheumatologist, La Laguna, Spain, ¹⁰Hospital General Universitario Elda, Elda, Spain, ¹¹Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ¹²Hospital Universitario de Burgos, Burgos, Spain, ¹³Complexo Hospitalario Universitario de Ourense, Ourense, ¹⁴Sociedad Española de Reumatología, Madrid, Spain, ¹⁵MD, PhD, Madrid, Madrid, Spain
Background/Purpose: Failure of a first-line anti-TNF in axial spondyloarthritis (axSpA) is common, and when it occurs, there are no randomized clinical trials (RCTs) comparing the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].